Genetron Holdings

Genetron Holdings is a prominent precision oncology platform company established in 2013, headquartered in Beijing, China. The firm specializes in advanced cancer molecular profiling, leveraging sophisticated molecular biology and data science to revolutionize cancer treatment protocols. By providing a comprehensive oncology portfolio, Genetron Holdings addresses critical needs across the entire cancer management spectrum, including early screening, precise diagnosis, treatment recommendations, and continuous disease monitoring. The company maintains a strong market presence by partnering with global biopharmaceutical entities to deliver customized diagnostic services and products.

Operating with a workforce of 500-1,000 employees across 2 locations, the organization focuses on integrating genomic data into clinical practice. Their technical infrastructure supports seamless molecular diagnostic workflows, ensuring high-quality detection and monitoring capabilities for healthcare providers. Meet Genetron Holdings's team to understand the leadership driving these innovations in the oncology sector. The company’s commitment to research and development remains central to its operational strategy, facilitating the deployment of IVD kits and advanced genomic tools that enhance patient outcomes in complex medical environments.

Financially, Genetron Holdings demonstrates significant market activity, evidenced by its Series C funding round of $61.0M in 2018. The company reported annual revenue of $90.5M, reflecting its robust position within the competitive business services and oncology diagnostic markets. As a publicly traded entity on the NASDAQ under the ticker GTH, the firm continues to expand its influence in the Asia-Pacific region. Explore financial highlights to review detailed performance metrics and historical growth data. This strategic focus on scalable diagnostic solutions positions the company as aView more...